spacer
home > ebr
PUBLICATIONS

European Biopharmaceutical Review

 

European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:

Advertising

David Hirsh

Giovanni Farina 

Editorial 

Emma Naks
  

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.



View the
digital version
of EBR


ebr
 
 
Featured in this issue
BioDevelopment and Regulatory
Patent Protection

The Secret of Success


Bioproduction processes can offer companies the chance to exploit new subject matter to extend the patent life of a drug. This rise in second-generation copyrights is prompting legal moves, says Paul Calvo at Sterne, Kessler, Goldstein and Fox.
INDUSTRY DYNAMICS
Clinical Research Outsourcing

Merging Markets


Vijaya Vulapalli at GBI Research explores how clinical research outsourcing partners are set to cash in on the opportunities presented by pharma’s tough times.
  BioDevelopment and Regulatory
Regulatory Update

New Twists for Orphans


Fresh changes at the FDA have had important implications for the orphan drug development process. Timothy Coté at Coté Orphan Consulting guides companies and sponsors through the regulatory minefield.

spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

Banner of Samedan app.EBR on Samedan
Banner of Agilent.EBR on Samedan
 
Industry Events

Pharmaceutical and Medical Device Packaging and Labelling

24-25 September 2014, Berlin, Germany

The Pharmaceutical and Medical Device Packaging and Labelling 2014 conference will take place in Berlin, Germany on 24th – 25th September 2014.  Returning for its 13thyear, the event will present itself as a unique forum for industry leaders to discuss and evaluate potential solutions to the biggest challenges within this industry sector.
More info >>

 
News and Press Releases

Gerresheimer at CPhI 2014 - Innovative Packaging Solutions in Plastic and Glass

Düsseldorf, September 2, 2014 – Gerresheimer will be showcasing innovative glass and plastic packaging solutions for the pharmaceutical industry in the Innopack exhibition area at CPhI Paris from October 7 to 9, 2014. The comprehensive product range extends from simple pharmaceutical vials to complex drug delivery systems. Two Gerresheimer experts will also be giving presentations on ready-to-fill sterile syringes on October 7.
More info >>

air transport logo

 

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement